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                                     INTRODUCTION
The metabolic syndrome is a collection of frequently associated cardiovascular 
risk factors  that  tend to  aggregate  in  selected patient  populations  and that,  together, 
increase coronary and cardiovascular mortality, and total mortality.  The World Health 
Organization, has used this term to indicate a state of insulin resistance with pervasive 
dysmetabolism secondary  to  the state  of  insulin  resistance.  Conceptualization  of  the 
metabolic  syndrome  as  a  unique,  high  risk  cardiovascular  state,  as  defined  by  the 
National Cholesterol Education Program (NCEP), is gaining acceptance as the basis for 
diagnosing the metabolic syndrome.   BMI remains an independent correlate of cardiac 
function,  even  after  adjusting  for  age,  mean  arterial  pressure,  LV mass  index,  and 
insulin. Previous smaller studies have focused on conventional methods such as LVEF 
and fractional shortening, which are relatively insensitive and thus unable to detect early 
preclinical  changes.  The  more  sensitive,  newer  echo  techniques  have  been  used  to 
demonstrate the presence of subclinical LV changes in young obese patients in recent 
studies. These functional changes are matched by changes in LV morphology.
    
REVIEW OF LITERATURE
The  metabolic  syndrome represents  a  clustering  of  cardiovascular  risk  factors 
affecting around 22% of the adult population in industrialized countries and over 40% of 
the those aged 50 and older. These risk factors have been shown to act synergistically, 
via mechanisms poorly defined, to increase the risk of adverse cardiovascular events 
including coronary artery disease (CAD) and congestive heart failure, and are associated 
with high cardiovascular morbidity and mortality.1
                In 1988, Reaven first introduced the concept that insulin resistance clusters 
with glucose intolerance, dyslipidemia, and hypertension to increase cardiovascular risk 
[Reaven, 1988]. These abnormalities were related to insulin resistance (IR) by cause-
effect relationships and it was emphasized that IR alone is insufficient to alter glucose 
tolerance. IR and hyperinsulinemia are neither strictly necessary nor sufficient to alter 
lipid metabolism, blood pressure, or vascular function. Each of these systems is under 
multifactorial  control,  and  defects  in  one  or  more  steps  of  its  effector  pathway  are 
necessary to drive the system out of balance [Ferrannini, 2007]. In the 1990s, the so-
called  insulin  resistance  syndrome  transmuted  into  the  clinical  metabolic  syndrome 
(MetS), which has now taken hold in the medical literature.It represents a global public 
health problem. Since 1988, when Reaven first systematically described it, an abundance 
of  research  has  advanced  an  understanding  of  the  pathophysiology,  epidemiology, 
prognostic implications, and therapeutic strategies related to the Metabolic syndrome. 
Reaven’s  first  definition  of  the  Metabolic  syndrome  included  these  components: 
hyperglycemia, abdominal  obesity, hypertriglyceridemia, low high-density lipoprotein 
cholesterol  concentration,  and hypertension.  Its  pathogenesis,  unified by the putative 
mechanism of  insulin  resistance,  was  thought  to  be  related  to  interactions  between 
sedentary lifestyle, diet, and genetic factors. In 1998, the American Diabetes Association 
proposed that Metabolic syndrome is comprised of glucose intolerance, central obesity, 
dyslipidemia  (including  increased  triglycerides,  decreased  high-density  lipoprotein 
cholesterol concentration, and increased small dense low density lipoprotein cholesterol 
concentration), hypertension, increased prothrombotic and antifibrinolytic factors, and 
risk  for  atherosclerotic  disease2; In  1999,  the  World  Health  Organization  (WHO) 
codified specific components and thresholds for the Metabolic syndrome, and in 2003 
the  U.S.  National  Cholesterol  Education  Program  (NCEP)  redefined  the  Metabolic 
syndrome in an attempt to simplify the clinical application of its criteria and improve its 
recognition.  Despite  these  efforts,  there  exists  no  genuine  consensus  of  the  unique 
components that comprise the Metabolic Syndrome3.
Clinical Diagnosis of the Metabolic Syndrome
Several different sets of criteria have been proposed during the past decade for 
diagnosis  of  the  metabolic  syndrome.  In  2001,  the  National  Cholesterol  Education 
Program  (NCEP)  Adult  Treatment  Panel  III  (ATP  III)  proposed  a  simple  set  of 
diagnostic criteria based on common clinical measures including waist circumference, 
triglycerides, HDL-C, blood pressure, and fasting glucose level. The presence of defined 
abnormalities  in any 3 of  these 5 measures constitutes  a diagnosis  of  the metabolic 
syndrome1. The ATP III criteria for the metabolic syndrome have been widely used in 
both clinical practice and epidemiological studies. The criteria also have the advantage 
of avoiding emphasis on a single cause. In the absence of compelling scientific reasons 
for change, the AHA and NHLBI affirm the overall utility and validity of the ATP III 
criteria  and  propose  that  they  continue  to  be  used  with  minor  modifications  and 
clarifications.
 These modifications and clarifications include allowing for adjustment of waist 
circumference to lower thresholds when individuals or ethnic groups are prone to insulin 
resistance; allowing triglycerides, HDL-C levels, and blood pressure to be counted as 
abnormal when a person is taking drug treatment for these factors; clarifying that the 
definition of  elevated blood pressure  is  a level  that  exceeds the threshold for  either 
systolic or diastolic pressure; and reducing the threshold for counting elevated fasting 
glucose from >110 mg/dL to >100 mg/dL, in accordance with the American Diabetes 
Association’s (ADA’s) revised definition of impaired fasting glucose (IFG). Recently, 
the International Diabetes Federation (IDF) has proposed a set of clinical criteria that are 
similar  to  those of  the updated ATP III  criteria.  In fact,  thresholds are  identical  for 
triglycerides, HDL-C, blood pressure, and plasma glucose. The updated AHA/NHLBI 
diagnostic  criteria  maintain  ATP  III  waist  circumference  thresholds  for  Americans, 
except that a lower threshold can be invoked for individuals who are especially prone to 
insulin resistance, particularly Asian Americans. Abdominal obesity is highly correlated 
with and easier to measure than other indicators of insulin resistance. The IDF therefore 
concluded  that  abdominal  obesity  incorporates  both  concepts  of  obesity  and  insulin 
resistance as being the 2 major underlying risk factors of the metabolic syndrome4; thus, 
they  made  increased  waist  circumference  a  required  element  for  diagnosing  the 
metabolic  syndrome.   In  the  updated  ATP  III  classification,  increased  waist 
circumference  is  not  deemed  a  necessity  if  3  other  risk  factor  criteria  are  present. 
Despite these minor differences in criteria for diagnosis, in the US population,
updated ATP III and IDF criteria identify essentially the same individuals as having the 
metabolic syndrome5. 
Features of the metabolic syndrome as defined according to the Adult Treatment 
Panel III of the National Cholesterol Education Program (ATPIII-NCEP) are:
1. Waist circumference > 102 cm in men and > 88 cm in women;
2. Fasting serum triglycerides ≥ 150 mg/dl;
3. High-density lipoprotein (HDL) cholesterol < 40 mg/dl in men and < 50 mg/dl in 
women;
4. High blood pressure: systolic blood pressure ≥ 130 mmHg and/or diastolic blood 
pressure ≥ 85 mmHg or antihypertensive drug treatment;
5. High glucose levels: fasting serum glucose ≥ 110 mg/dl or clinical diagnosis of 
diabetes.
The World Health Organisation’s clinical criteria for the metabolic syndrome.
Insulin resistance, identified by one of the following:
-  Type 2 diabetes mellitus
-  Impaired fasting glucose
-  Impaired glucose tolerance
-  Or for those with normal fasting glucose levels (<110 mg/dL), glucose uptake 
below the lowest quartile for background population under
          investigation under hyperinsulinaemic, euglycaemic conditions
Plus any 2 of the following:
-  Antihypertensive medication and/or high blood pressure (≥140/90 mm Hg )
- Plasma triglycerides ≥150 mg/dL
- HDL-C <35 mg/dL in men or <39 mg/dL in women
- Body mass index >30 kg/m2 and/or waist to hip ratio >0.9 in men             and > 
0.85 in women                
- Urinary albumin excretion rate ≥20 microgram /min or albumin:creatinine  ratio 
≥30   mg/g.
The International Diabetes Federation’s definition of the metabolic syndrome.
Central obesity (defined as waist circumference ≥94 cm for Europid men and ≥80 
cm for Europid women, with ethnicity specific values for other groups*)
Plus any 2 of the following 4 factors:
-  Raised  triglyceride  level  ≥150  mg/dL,  or  specific  treatment  for  this  lipid 
abnormality
-  Reduced  HDL-C  <40  mg/dL  in  males,  <50  mg/dL  in  females,  or  specific 
treatment for this lipid abnormality
-  Raised  BP:  systolic  BP  ≥130  or  diastolic  BP  ≥85  mm  Hg,  or  treatment  of 
previously diagnosed hypertension
-  Raised  fasting  plasma  glucose  ≥100  mg/dL,  or  previously  diagnosed  type  2 
diabetes
*South Asians and Chinese: ≥90 cm for males, ≥80 cm for females. 
Japanese: ≥85 cm for males, ≥90 cm for females. 
Ethnic South and Central  Americans:  Use South Asian recommendations until 
more specific data are available. 
East  Mediterranean,  Middle  East  (Arab)  and  sub-Saharan  populations:  Use 
European data until more specific data are available.
Modified ATP-III-1 [MS1]: WC cutoffs  ≥90 cm for men and  ≥80 cm for women. 
Criteria from 2 to 5 were unchanged as per the NCEP ATP-III description above.
Modified ATP-III-2 [MS2]: BMI cutoff at  ≥23 Kg/m2 in addition to the criteria 
used in MS1.
Modified WHO [MS3]: The definitions were same as for the WHO criteria except 
for WHR of  ≥0.89 in males and  ≥0.81 in females and a BMI ≥23 kg/m.
Distinct  clinical  features and metabolic  predispositions are  frequently  noted in 
people  with  abdominal  adiposity,  insulin  resistance,  dyslipidemia,  and  HTN.  To 
simplify the recognition of such a clustering, the WHO laid down definitive criteria 
(WHO 1999), followed by the MS definition of NCEP–ATP-III (ATP-III 2001) and IDF 
(Albert et al 2005). The Center for Disease Control and Prevention and US Department 
of  Health  and  Human  Services  have  attributed  a  specific  code  to  “dysmetabolic 
syndrome” (ICD #277.7) (CDC 2002) in the 9th revision in clinical classification, thus 
bestowing it with an implicative dignity.
Clinical  criteria  of  the  American  Association  of  Clinical  Endocrinologists  for 
diagnosis of the Insulin Resistance Syndrome
Diagnosis depends on clinical judgement based on risk factors.
Risk factor components Cut-off points for abnormality
Overweight/obesity Body mass index ≥25 kg/mÇ
Elevated triglycerides ≥150 mg/dL
Low HDL-C
Men <40 mg/dL
Women <50 mg/dL
Elevated blood pressure ≥130/85 mm Hg
2-hour post-glucose challenge >140 mg/dL
Fasting glucose 110-126 mg/dL
Other risk factors Family history of type 2 diabetes 
mellitus, hypertension, or 
cardiovascular disease
Polycystic ovary syndrome
Sedentary lifestyle
Advancing age
Ethnic groups having high risk for 2 
diabetes mellitus or cardiovascular 
disease
Epidemiology of the Metabolic syndrome:
Reviewing the literature for studies investigating the epidemiology of the MetS 
reveals  limited  and  conflicting  data.  Asian  Indians  are  a  high-risk  population  with 
respect to diabetes mellitus and CVD and the numbers are consistently on the rise (Enas 
et  al  1992;  Enas  and Senthilkumar  2001).  It  has  long been doubted  that  the  above 
standard  definitions  of  MS  under-  represents  its  prevalence  in  the  Asian  Indian 
community, thereby delaying the commencement of definite preventive and therapeutic 
efforts  in  many  individuals.  The  results  of  various  studies  have  appreciated  ethnic 
variation in clinical measures and disease outcomes in different populations (Anand et al 
2003; Tan et al 2004). 
     Part of the problem lies in the cutoffs for obesity as defined by the WHO and 
ATP-III, which are not valid for Asian Indians. This population is of smaller build, has 
high insulin resistance and a dysmetabolic adipocyte milieu at considerably lower BMI 
and abdominal adiposity as identified by a large WC (Cooppan 2005). In the wake of 
ongoing debate and a lack of consensus, the WHO recognized the need for population 
specifi  c  cutoff  definitions  in  order  to  make the diagnosis  of  MS more precise  and 
modified the BMI cutoff in Asians (WHO 2004). Also,  the IDF (Albert  et  al  2005) 
published consensus cutoff for WC that are more ethnic-specific, based on the Chinese, 
Malay,  and Asian Indian populations.  In one study,  three candidate  definitions were 
revised for MS by substituting the above modified cutoffs for BMI and WC, as also the 
WHR  in  the  ATP-III  and  WHO  definitions  while  IDF  criteria  was  independently 
assessed in this study. A consistent gain in MS diagnosis was achieved by applying the 
modified definitions over the standard ones. Maximum gain was obtained in the MS2 
group  as  defined  by  applying  modified  WC  and  BMI  over  and  above  the  MS1 
definition, which used only a modification in WC in its criteria. A comparable finding 
was reported using modified ATP-III criteria for anthropometry, which included skin 
fold thickness measurements in their candidate definition (Misra et al 2005). The IDF 
proposed that  central  obesity  is  an  essential  component  of  MS,  while  the American 
Heart Association/National Heart,
Lung and Blood Institute (AHA/NHLBI) opines that it is an optional component similar 
to the other MS factors. Also, the IDF supported a modified cut off in impaired fasting 
glucose (IFG) levels ≥ 100 mg/dL as compared with ≥110 mg/dL set by other criteria. 
The  various  definitions  were  applied  to  a  cohort  with  high risk  for  CAD where all 
participants had a family history of premature onset of CAD7. MS prevalence was higher 
in that cohort in comparison to other studies. At baseline, ATP-III labeled a significantly 
higher  proportion  of  people  with  MS  when  compared  with  the  WHO  criteria. 
Distribution of MS across various age groups showed  a gradual increase in prevalence 
with advancing age in both males and females in that cohort with maximum prevalence 
in the 50–59 age group. Distribution of MS prevalence was similar across age groups in 
MS1, MS2, and IDF categories. Tan and colleagues (2004) reported a similar trend in 
prevalence. 
In this context, early detection of MS would be of immense importance to deploy 
prophylactic measures against component risk factors of MS. The modified     ATP-III 
criteria [MS1 and MS2] were able to identify greater number of young people with MS 
[30–39 yrs] than the WHO criteria.  Hence the above modifications do indicate their 
ability to identify the ‘high-risk subjects’ much earlier.
The NCEP definition is more flexible as it can diagnose MS even in the absence 
of glucose intolerance, which in itself is a predisposition to dysmetabolic dyslipidemia, 
an obesity phenotype and a pro-inflammatory status. The WHO criteria, on the other 
hand, mandate the presence of diabetes with the inclusion of microalbuminuria, which is 
not only a marker for renal disease, but also for CVD. By the time most patients receive 
a diagnosis of diabetes, they are more than likely to have developed micro- or macro-
vascular disease (Enas et al 1992). It can thus be expected that a greater proportion of 
the  patients  will  have  CVD,  if  MS  is  determined  based  on  the  WHO  guidelines. 
Employing  the  MS2  and  MS3  criteria,  those  with  MS  but  without  CVD  were 
identified .Subjects with MS were on an average ten years older than those without the 
syndrome.  Significantly  larger  number  of  people  with  MS  were  hypertensive  and 
diabetic with higher anthropometric parameters and incidence of CVD when compared 
with those without MS8. BMI showed correlation with WC but not with WHR, which 
indicates that WC and BMI may be better predictors of MS when compared with WHR 
in Asian Indians. Kurpad and colleagues (2003) found similar correlation between WC 
and BMI and suggest that WC is a better marker of abdominal obesity than WHR.
                         
                         
Age-adjusted prevalence of the metabolic syndrome among 8,814 U.S. adults at 
least  20  years  of  age,  by  sex  and  race  or  ethnicity,  from the  National  Health  and 
Nutrition Examination Survey III, 1988-19946.
Components of Metabolic Syndrome
ATP  III1  identified  6  components  of  the  metabolic  syndrome  that  relate  to 
CVD9,10,11:
 Abdominal obesity (↑ waist circumference)
 Atherogenic dyslipidaemia (↑ triglycerides, ↓ HDL-C, ↑ ApoB, ↑ small LDL 
particles)
 Elevated blood pressure
 Insulin resistance ± glucose intolerance (IFG and/or IGT)
 Proinflammatory state (↑ hsCRP)
 Prothrombotic state (↑ PAI-1, ↑ FIB)
 Other  features:  endothelial  dysfunction,  microalbuminuria,  polycystic  ovary 
syndrome, hypoandrogenism, non-alcoholic fatty liver disease, hyperuricaemia, 
and disturbances of the phosphate and magnesium metabolism
Clinical syndromes associated with the metabolic syndrome.9,10 
1. Type 2 diabetes mellitus
2. Cardiovascular disease
3. Essential hypertension
4. Polycystic ovary syndrome
5. Non-alcoholic fatty liver disease
6. Certain forms of cancer
7. Sleep apnoea
These components of the metabolic syndrome constitute a particular combination 
of what ATP III terms underlying, major, and emerging risk factors. According to ATP 
III, underlying risk factors for CVD are obesity (especially abdominal obesity), physical 
inactivity,  and  atherogenic  diet;  the  major  risk  factors  are  cigarette  smoking, 
hypertension,  elevated  LDL  cholesterol,  low  HDL  cholesterol,  family  history  of 
premature  coronary  heart  disease  (CHD),  and  aging;  and  the  emerging  risk  factors 
include  elevated  triglycerides,  small  LDL  particles,  insulin  resistance,  glucose 
intolerance, proinflammatory state, and prothrombotic state. For present purposes, the 
latter  5  components  are  designated  metabolic  risk  factors.  Each  component  of  the 
metabolic syndrome will be briefly defined.
• Abdominal  obesity  is  the  form  of  obesity  most  strongly  associated  with  the 
metabolic syndrome. It presents clinically as increased waist circumference.
• Atherogenic  dyslipidemia  manifests  in  routine  lipoprotein  analysis  by  raised 
triglycerides and low concentrations of HDL cholesterol. A more detailed analysis 
usually  reveals  other  lipoprotein  abnormalities,  eg,  increased  remnant 
lipoproteins,  elevated  apolipoprotein  B,  small  LDL  particles,  and  small  HDL 
particles. All of these abnormalities have been implicated as being independently 
atherogenic.
• Elevated blood pressure strongly associates with obesity and commonly occurs in 
insulin-resistant persons. Hypertension thus commonly is listed among metabolic 
risk  factors.  However,  some  investigators  believe  that  hypertension  is  less 
“metabolic” than other metabolic-syndrome components. Certainly, hypertension 
is multifactorial in origin
• Insulin  resistance  is  present  in  the  majority  of  people  with  the  metabolic 
syndrome. It strongly associates with other metabolic risk factors and correlates 
univariately  with  CVD  risk5.  These  associations,  combined  with  belief  in  its 
priority, account for the term insulin resistance syndrome. Even so, mechanisms 
underlying  the  link  to  CVD  risk  factors  are  uncertain,  hence  the  ATP  III’s 
classification  of  insulin  resistance  as  an  emerging  risk  factor.  Patients  with 
longstanding insulin resistance frequently manifest  glucose intolerance, another 
emerging  risk  factor.  When  glucose  intolerance  evolves  into  diabetes-level 
hyperglycemia, elevated glucose constitutes a major, independent risk factor for 
CVD.
• A proinflammatory state, recognized clinically by elevations of C-reactive protein 
(CRP),  is  commonly  present  in  persons  with  metabolic  syndrome.  Multiple 
mechanisms seemingly underlie elevations of CRP. One cause is obesity, because 
excess adipose tissue releases inflammatory cytokines that may elicit higher CRP 
levels.
• A prothrombotic state, characterized by increased plasma plasminogen activator 
inhibitor (PAI)-1 and fibrinogen,  also associates with the metabolic syndrome. 
Fibrinogen, an acute-phase reactant like CRP, rises in response to a high-cytokine 
state.  Thus,  prothrombotic  and  proinflammatory  states  may  be  metabolically 
interconnected.
Pathogenesis of Metabolic Syndrome
The metabolic syndrome seems to have 3 potential etiological categories: obesity 
and disorders of adipose tissue; insulin resistance; and a constellation of independent 
factors  (eg,  molecules  of  hepatic,  vascular,  and  immunologic  origin)  that  mediate 
specific components of the metabolic syndrome. Other factors—aging, proinflammatory 
state, and hormonal changes—have been implicated as contributors as well.
Obesity and Abnormal Body Fat Distribution
ATP III considered the “obesity epidemic” as mainly responsible for the rising 
prevalence  of  metabolic  syndrome.  Obesity  contributes  to  hypertension,  high  serum 
cholesterol, low HDL cholesterol, and hyperglycemia, and it otherwise associates with 
higher CVD risk. Abdominal obesity especially  correlates with metabolic risk factors. 
Excess adipose  tissue releases  several  products  that  apparently  exacerbate  these  risk 
factors.  They  include  nonesterified  fatty  acids  (NEFA),  cytokines, PAI-1,  and 
adiponectin. A high plasma NEFA level overloads muscle and liver with lipid, which 
enhances  insulin resistance.  High  CRP  levels  accompanying  obesity  may signify 
cytokine  excess  and  a  proinflammatory  state.  An elevated  PAI-1  contributes  to  a 
prothrombotic state, whereas low adiponectin levels that accompany obesity correlate 
with worsening  of  metabolic  risk  factors.  The  strong  connection between  obesity 
(especially  abdominal  obesity)  and risk  factors  led  ATP III  to  define  the  metabolic 
syndrome essentially as a clustering of metabolic complications of obesity.
Insulin Resistance
A second category of causation is insulin resistance. Many investigators place a 
greater priority on insulin resistance than on obesity in pathogenesis. They argue that 
insulin resistance, or its accomplice, hyperinsulinemia, directly causes other metabolic 
risk factors. Identifying a unique role for insulin resistance is complicated by the fact 
that it is linked to obesity. Insulin resistance generally rises with increasing body fat 
content, yet a broad range of insulin sensitivities exists at any given level of body fat.4 
Most  people  with  categorical  obesity  (body  mass  index  [BMI]  ≥  30  kg/m2)  have 
postprandial hyperinsulinemia and relatively low insulin sensitivity, 5 but variation in 
insulin sensitivities exists even within the obese population.4 Overweight persons (BMI 
≥ 25 to 29.9 kg/m2) likewise exhibit a spectrum of insulin sensitivities, suggesting an 
inherited  component  to  insulin  resistance.  In  some  populations  (eg,  South  Asians), 
insulin  resistance  occurs  commonly  even  with  BMI  _25  kg/m2  and  apparently 
contributes to a high prevalence of type 2 diabetes and premature CVD. South Asians 
and others who manifest insulin resistance with only mild-to-moderate overweight can 
be  said  to  have  primary  insulin  resistance.  Even  with  primary  insulin  resistance, 
however,  weight  gain  seems to  enhance  insulin  resistance  and metabolic  syndrome. 
Thus, dissociation of obesity and primary insulin resistance in patients with metabolic 
syndrome is difficult. This is not to say that insulin resistance per se does not play a 
significant role in causation of metabolic syndrome. When insulin-resistant muscle is 
already  overloaded  with  lipid  from high  plasma  NEFA  levels,  some  excess  NEFA 
presumably is diverted to the liver, promoting fatty liver and atherogenic dyslipidemia. 
Hyperinsulinemia may enhance output  of  very low- density  lipoprotein triglycerides, 
raising  triglycerides.  Insulin  resistance  in  muscle  predisposes  to  glucose  intolerance, 
which can be worsened by increased hepatic gluconeogenesis in insulin-resistant liver. 
Finally, insulin resistance may raise blood pressure by a variety of mechanisms.
Complex interactions of genetic, perinatal, nutritional and other acquired factors 
in development of insulin resistance, type 2 diabetes and coronary heart disease in South 
Asians are shown below:
Independent  Factors  That  Mediate  Specific  Components  of  the  Metabolic 
Syndrome
Beyond obesity and insulin resistance, each risk factor of the metabolic syndrome 
is subject to its own regulation through both genetic and acquired factors. This leads to 
variability in expression of risk factors. Lipoprotein metabolism, for instance, is richly 
modulated  by  genetic  variation;  hence,  expression  of  dyslipidemias  in  response  to 
obesity and/or insulin resistance varies considerably. The same holds for blood pressure 
regulation.  Moreover,  glucose levels  depend on insulin-secretory capacity  as  well  as 
insulin sensitivity. This variation in distal regulation cannot be ignored as an important 
factor in causation of metabolic syndrome.
Other Contributing Factors
Advancing age probably affects all levels of pathogenesis, which likely explains 
why  prevalence  of  the  metabolic  syndrome  rises  with  advancing  age.  Recently,  a 
proinflammatory state has been implicated directly in causation of insulin resistance, as 
well  as  atherogenesis.  Finally,  several  endocrine  factors  have  been  linked  to 
abnormalities in body-fat distribution and hence indirectly to metabolic syndrome. Thus, 
pathogenesis  of  the  metabolic  syndrome is  complex and ripe  with  opportunities  for 
further research.
Issue of Oral Glucose Tolerance Test
Both  WHO  and  AACE  include  IGT,  detected  by  oral  glucose  tolerance  test 
(OGTT)  or  2-hour  postglucose  challenge,  among  the  risk  factors  for  metabolic 
syndrome. ATP III did not include it because of the added inconvenience and cost of 
OGTT in clinical practice9,10. 
Therapeutic Implications Obesity and Body Fat Distribution as Targets of Therapy
ATP  III  recommended  that  obesity  be  the  primary  target  of  intervention  for 
metabolic  syndrome.  First-line  therapy  should  be  weight  reduction  reinforced  with 
increased  physical  activity.  Weight  loss  lowers  serum cholesterol  and  triglycerides, 
raises  HDL  cholesterol,  lowers  blood  pressure  and  glucose,  and  reduces  insulin 
resistance. Recent data further show that weight reduction can decrease serum levels of 
CRP and PAI-1. 
Insulin Resistance as Target of Therapy
If insulin resistance, whether primary or secondary to obesity, is in the chain of 
causation of  metabolic  syndrome,  it  would be an attractive target.  Certainly,  weight 
reduction  and  increased  physical  activity  will  reduce  insulin  resistance.  Insulin 
resistance as a target has caught the imagination of the pharmaceutical industry, and 
drug discovery is underway. Two classes of drugs are currently available that reduce 
insulin resistance. These are metformin and insulin sensitizers such as thiazolidinediones 
(TZDs). Metformin has long been used for treatment of type 2 diabetes. In UKPDS, 
metformin apparently reduced new onset CHD in obese patients with diabetes5,11. In the 
Diabetes Prevention Program, metformin therapy prevented (or delayed) onset of type 2 
diabetes  in  persons  with  IGT.  There  are,  however,  no  CVD  end-point  studies  on 
metformin  treated  patients  with  metabolic  syndrome12.  Thus,  at  present,  metformin 
cannot be recommended for the express purpose of reducing risk for CVD in persons 
with the metabolic syndrome.
TZDs  currently  are  approved  for  treatment  of  type  2  diabetes15.  They  reduce 
insulin resistance, favorably modify several metabolic risk factors, and reverse abnormal 
arterial responses. Nonetheless,  no clinical trial data yet exist to document benefit in 
CVD risk reduction. Thus, in spite of promise, TZDs cannot be recommended at present 
for preventing CVD in patients with either metabolic syndrome or diabetes10,12.
Specific Metabolic Risk Factors as Targets of Therapy
Atherogenic Dyslipidemia
Although statins typically are recognized to be LDL-lowering drugs, they reduce 
all apolipoprotein B–containing lipoproteins. Recent subgroup analyses of statin trials 
reveal  that  statins  reduce risk for  CVD events  in patients  with metabolic  syndrome. 
Fibrates  also  favorably  modify  atherogenic  dyslipidemia  and  may  directly  reduce 
atherogenesis. Post hoc analysis of recent fibrate trials strongly suggests that they reduce 
CVD end points  in  patients  with atherogenic  dyslipidemia  and metabolic  syndrome. 
Moreover,  clinical  studies demonstrate that  abnormal lipoprotein patterns are doubly 
improved  by  combined  statin-fibrate  therapy,  but  just  how  much  this  combination 
reduces CVD events beyond statins alone awaits demonstration with controlled clinical 
trials.
Elevated Blood Pressure
There  is  full  agreement  that  hypertensive  patients  with  metabolic  syndrome 
deserve lifestyle therapies to reduce blood pressure. In addition, antihypertensive drugs 
should be used as recommended by hypertension guidelines. 
Prothrombotic State
No drugs are available that target PAI-1 and fibrinogen. An alternative approach 
to the prothrombotic state is antiplatelet therapy. For example, low-dose aspirin reduces 
CVD events in both secondary and primary prevention. Thus, use of aspirin for primary 
prevention  in  patients  with  metabolic  syndrome  is  promising.  According  to  current 
recommendations,  low-dose aspirin  therapy has  a  favorable  efficacy/side effect  ratio 
when 10-year risk for CHD is > 10%.
Proinflammatory State
There is growing interest in development of drugs to dampen the proinflammatory 
state. Several lipid-lowering drugs will reduce CRP levels, which could reflect an anti-
inflammatory action.
Hyperglycemia
When patients with metabolic syndrome develop type 2 diabetes, they are at high 
risk for CVD. All CVD risk factors should be intensively reduced. In addition, glucose 
levels should be appropriately treated with lifestyle therapies and hypoglycemic agents 
as needed to keep hemoglobin A1c levels below guideline targets.
Cardiac changes in structure and function in metabolic syndrome
 LV Mass
Increased LV mass is associated with coronary heart disease, stroke, and heart 
failure. Metabolic syndrome has been associated with prevalent CVD in most studies, 
including the population-based Strong Heart Study27.
This observation is of clinical importance because treatment leading to regression 
in LV mass can improve cardiovascular  prognosis.  In one study (Bilal Aizaz,  2008) 
women with metabolic syndrome had a greater LV mass index than women without 
metabolic  syndrome,  demonstrating  that  women  with  metabolic  syndrome  already 
manifest  measurable  abnormalities  in  LV  structure27.  In  another  study(  Lisa  de  las 
Fuentes, 2006) although LV volumes and LVEF were similar among the three groups of 
Absent metabolic syndrome, Pre-Metabolic syndrome and metabolic syndrome, RWT 
and LVM/Ht2 and the prevalence of diastolic dysfunction increased progressively from 
the Absent to the Pre-Metabolic Syndrome and Metabolic Syndrome groups28. Of note, 
the  Absent  group,  while  not  meeting  any  criteria  for  metabolic  syndrome,  did  not 
represent  a ‘normal control’  group since 47% were either overweight or  obese. This 
study revealed that while each of the variables contributing to metabolic syndrome was 
correlated with LV relaxation (i.e. Veglobal) in univariate analyses (HDL-C excluded), 
only  diastolic  blood  pressure,  waist  circumference,  and  triglyceride  remained 
independently associated with Veglobal in models that also included age and LV mass28.
   Echocardiography,  performed  at  1  of  4  sites  in  the  Atherosclerosis  Risk  in 
Communities (ARIC) Study, was used to assess LV dimensions in 1572 black women 
and men aged 49 to 75 years in 1993–1996. Participants were categorized by number of 
metabolic syndrome characteristics (hypertension, dyslipidemia [low HDL cholesterol 
or high triglycerides], and glucose intolerance). Age-adjusted mean LV mass indexed by 
height  (g/m2)  increased  in  a  stepwise  gradient  with  increasing  number  of  metabolic 
syndrome disorders (none, any 1, any 2, all 3) in both women and men (125.1, 143.9, 
153.7,  169.3  and 130.5,  148.7,  160.8,  170.2,  respectively;  P<0.001,  tests  for  trend). 
Associations were diminished slightly by adjustment for smoking, alcohol intake, and 
education; additional adjustment for waist circumference resulted in some attenuation, 
but associations remained statistically significant. Analyses focusing on components of 
LV mass revealed that posterior wall and interventricular septal thickness, but not LV 
chamber  size,  were  significantly  and  independently  associated  in  general  with  the 
number of metabolic syndrome disorders. Consistent with these findings, relative wall 
thickness  was  also  associated  with  number  of  disorders.  Associations  were  similar 
across age and central adiposity. Hypertension had a strong influence on LV mass with 
additional contributions from dyslipidemia and glucose intolerance; strong synergistic 
effects of the syndrome beyond its individual components were not observed. In another 
cross-sectional study of the general population by Ana Azevedo. Increasing severity of 
metabolic  syndrome  was  associated  with  increasingly  compromised  structure  and 
function of the heart. This association was independent of Framingham risk score for 
indirect  indices  of  diastolic  dysfunction  but  not  systolic  dysfunction,  and  was  not 
explained by blood pressure level. Parameters of left ventricular geometry patterns, left 
atrial diameter and diastolic dysfunction maintained this trend when taking into account 
the 10-year  predicted risk of coronary heart disease by the Framingham score as an 
independent variable, while left ventricular systolic dysfunction did not. The prevalence 
of  left  ventricular  diastolic  dysfunction,  and  the  mean  left  ventricular  mass,  left 
ventricular diameter and left atrial diameter increased significantly with the number of 
features  of  the  metabolic  syndrome  when  additionally  adjusting  for  systolic  blood 
pressure as a continuous variable.
LV Diastolic dysfunction
In  the  study  by  Lisa  de  las  Fuentes,  200628,  measurements  of  diastolic  (Ve) 
function worsened progressively from the Absent to the Pre-Metabolic Syndrome and 
Metabolic Syndrome groups, indicating impairment in diastolic function with increasing 
burden of metabolic syndrome.  Increased LV mass, RWT, and deceleration time have 
been  reported  in  hypertensive  subjects  with  metabolic  syndrome  compared  with  a 
hypertensive  cohort  without  the  syndrome.  In  the  Strong  Heart  Study,  those  with 
metabolic syndrome had greater LV mass and RWT and significantly lower E/A ratio; 
however, LV diastolic function was not characterized in Pre-Metabolic Syndrome. This 
study, by use of improved measures to detect LV relaxation (i.e. Ve), identifies a Pre-
Metabolic Syndrome group with impaired LV diastolic function. In 2 previous studies of 
patients with established hypertension,  the prevalence of LV diastolic dysfunction in 
metabolic syndrome was slightly increased (defined by Doppler flow and tissue Doppler 
imaging) or no different (defined by transmitral E/A velocity ratio only).30,32 Because 
blood pressure and serum glucose level both positively correlated with LV mass index 
and LV diastolic dysfunction in the study by Bilal Aizaz, 2008 , the modest magnitude 
of  the  increase  in  LV diastolic  dysfunction  among  persons  with  isolated  metabolic 
syndrome  was  likely  due  to  the  exclusion  of  patients  with  diabetes  mellitus  and 
hypertension. When those patients were included in the analysis, a progression was seen 
in LV diastolic dysfunction from no metabolic syndrome to isolated metabolic syndrome 
to  metabolic  syndrome  that  included  hypertension  and  diabetes.  This  progressive 
increase in LV mass index and LV diastolic dysfunction is consistent with the concept 
that  isolated  metabolic  syndrome is  an  early  stage  in  the  evolution  of  a  risk  factor 
complex,  which  is  reflected  in  progressive  adverse  remodeling  and  LV  diastolic 
dysfunction.
The association of LV diastolic dysfunction with metabolic syndrome in women 
was  most  strongly  influenced  by  waist  circumference  and  elevated  blood  pressure. 
Metabolic syndrome is characterized by insulin resistance, which is strongly associated 
with  central  obesity.  Indeed,  central  obesity  has  been  proposed  to  be  an  important 
underlying pathophysiologic factor in metabolic syndrome.
Echocardiographic techniques
   Diastolic dysfunction was assessed by pulsed-wave Doppler examination of mitral 
flow (before and during Valsalva maneuver) and pulmonary venous inflow, as well as 
by Doppler tissue imaging of the mitral annulus. Diastolic dysfunction was graded on a 
4-point ordinal scale: normal; mild diastolic dysfunction, defined as abnormal relaxation 
without increased LV end-diastolic filling pressure (peak early (E) to peak late [atrial] 
[A]  diastolic  filling  velocity  ratio  <0.75);  moderate  or  “pseudonormal”  diastolic 
dysfunction,  defined  as  abnormal  relaxation  with  increased  LV  end-diastolic  filling 
pressure (E/A ratio  of  0.75 to  1.5,  deceleration time >140 ms,  and 2 other  Doppler 
indices of elevated LV end-diastolic filling pressure); or severe diastolic dysfunction, 
defined as advanced reduction in compliance with restrictive filling (E/ A ratio >1.5, 
deceleration time <140 ms,  and Doppler  indices of  elevated LV end-diastolic filling 
pressure). 
Recent  advances  in  the  field  of  echocardiography  have  made  it  possible  to 
objectively quantify regional in addition to global myocardial function. Indeed, with the 
introduction of tissue deformation imaging echocardiographic techniques which include 
tissue  Doppler  imaging  (TDI)  and  speckle  tracking  (ST)  methods13,  the  inherent 
problems  with  earlier  echocardiographic  techniques  of  uni-dimensional  imaging  and 
limitations with regards to  regional  ventricular  wall  abnormalities  have largely  been 
overcome.
With these techniques, fractional change in length of a part of the myocardium 
compared to its original length, or strain (ε) is possible and as strain reflects deformation 
of  the  myocardium,  it  directly  describes  the  contraction/relaxation  pattern.  This 
technique also makes it possible to measure the strain rate (SR), which represents the 
rate of deformation. To optimally assess regional myocardial function, both strain and 
SR need to be calculated since they provide complementary information: end systolic 
strain estimates EF and peak systolic SR is a measure of contractility13,14.
      The  deformation  occurs  in  three  dimensions,  which  are  expressed  along three 
ventricular  coordinates:  a  longitudinal  and  circumferential  shortening  and  a  radial 
thickening. The deformation is calculated based on the relative change of the length of 
myocardial  fibers  during  the  cardiac  cycle  and  is  expressed  in  a  one  dimensional 
parameter  termed  strain  (ε).  The  local  end-systolic  strain  value  reflects  the  regional 
ejection fraction (EF) and the global LV end-systolic strain reflects the LVEF14.
  The cardiac deformation can also be represented graphically: S-wave represents 
the  negative  deflection  occurring  during  systole  with  the  peak  negative  deflection 
representing maximal longitudinal myocardial shortening (or peak systolic strain). With 
the start of diastole, the myocardial fibers start regaining their original length.
Graphically, it is represented in three phases: (1) the early or rapid filling phase 
(E-wave) followed by (2) a plateau phase or diastasis, and finally (3) atrial filling (A-
wave). The speed at which the myocardial deformation occurs is the SR and is expressed 
in s-1. SR depicts the change in strain over a period of time.
Myocardial deformation imaging techniques
Tissue Doppler Imaging and Speckle Tracking methods using B mode images are 
the two ultrasound based techniques used for evaluating myocardial deformation13,14.
Tissue Doppler Imaging
During  longitudinal  shortening  of  myocardium there  is  a  gradual  increase  in 
velocity from the apex to a maximum velocity at annular plane. This change in velocity 
called  velocity  gradient  is  used  to  calculate  the  SR by  measuring  the  difference  in 
velocity of the distal (v1) and the proximal (v2) point within defined region of interest 
(ROI), and the distance (x) between these two points. The following formula is used to 
calculate the strain rate:
SR   =   Δv/Δx = v1–v2/Δx.
Strain is calculated from the SR values by temporal integration. Strain rate is, as 
opposed  to  strain  alone,  especially  helpful  in  identifying  infarcted  tissue  where  the 
infracted segment does not deform during systole and there is no change in velocities. 
The calculated  SR would  be  zero  in  such case  although the  segment  could  show a 
displacement and velocity due to tethering of a functional neighboring segment.
Wall Motion Tracking Technology
Two  Dimensional  Tracking  (2DT)  is  an  application  of  pattern  matching 
technology  to  Ultrasound  Cine  data  also  commonly  known as  Speckle  Tracking.  A 
template image is created using a local myocardial region in the starting frame of the 
image data. In the next frame an algorithm searches for the local speckle pattern that 
most closely match the template. A movement vector is then created using the location 
of the template and the matching pattern in the subsequent frame. Multiple templates are 
used to observe movement of the entire myocardium. The process is then repeated by 
creating new templates and observing their movement in the subsequent frames until the 
entire cardiac cycle has been assessed. This method does not make use of Doppler infor-
mation, so there is no Doppler angle dependency.
                    
                       
Comparison Between TDI and Speckle Tracking
Parameter TDI Speckle tracking
One-dimensional/bidimensional use One dimensional Bi-dimensional
SR  variability  by  change  in 
insonation angle
Marked Minimal
Effect of artifacts like reverberations 
and side lobes
Marked Minimal
Calculation  of  ventricular  rotation 
and twist (additional parameters for 
LV function)
No Yes
Influence  of  tachycardia  on  image 
acquisition
Not influenced Undersampling
Training requirements Difficult Relatively easy
Post-processing time Longer Shorter
Reproducibility (for LV) Lesser Greater
                                                           
Clinical Applications13,14 
Tissue  deformation  imaging  has  given us  recent  new insights  into  ventricular 
function, adaptation, and mal-adaptation in response to pathology.
a. As  mentioned  previously,  these  techniques  can  be  used  to  accurately  and 
reproducibly measure global right and left ventricular function and regional wall 
deformation.
b. TDI is one of  the most  promising techniques for  guiding patient  selection for 
cardiac resynchronization therapy.
c. They can be used as robust techniques to determine diastolic dysfunction.
d. TDI has been shown to have a role in detecting cardiac ischemia and myocardial 
viability during stress echocardiography in patients with coronary artery disease 
and LV dysfunction. Doppler myocardial imaging is also a very sensitive marker 
of sub-endocardial dysfunction. 
e. Measurement  of  myocardial  velocities  can  discriminate  between  physiological 
and  pathological  hypertrophy  and  can  be  used  to  monitor  regression  of  LV 
hypertrophy under pharmacological treatment.
f. ST  has  been  suggested  to  reliably  distinguish  between  hypertrophic 
cardiomyopathy and hypertrophy associated with hypertension.
Metabolic Syndrome as a Risk Condition
It seems self-evident that a condition characterized by multiple risk factors will 
carry a greater risk for adverse clinical outcomes than will a single risk factor. This 
conclusion is implicit  in Framingham risk equations,  which incorporate many of the 
components of the metabolic syndrome. For this conference, Framingham investigators 
examined their  extensive database  for  the relation between metabolic  syndrome and 
future development of both CVD and diabetes. Their analysis was carried out on 3323 
Framingham offspring men and women (mean age, 52 years) in 8 years of follow-up.
Metabolic Syndrome as a Predictor of CVD
Individuals  with  metabolic  syndrome  are  at  increased  risk  for  CHD.10  In 
Framingham, the metabolic syndrome alone predicted 25% of all new-onset CVD. In the 
absence of diabetes,  the metabolic syndrome generally did not raise 10-year risk for 
CHD to 20%; this is the threshold for ATP III’s CHD risk equivalent. Ten-year risk in 
men with metabolic syndrome generally ranged from 10% to 20%. Framingham women 
with metabolic syndrome had relatively few CHD events during the course of the 8-year 
follow-up; this was due in part to the high proportion of women who were under 50 
years  of  age.  Although  the  metabolic  syndrome  in  these  women  appeared  to  be 
accompanied  by  higher  risk  for  CVD/CHD,  the  confidence  interval  was  wide,  and 
differences between those with and without metabolic syndrome were not statistically 
significant. 
Metabolic Syndrome as a Predictor of Diabetes
When the risk for new-onset diabetes was examined for the Framingham cohort, 
in both men and women, the presence of metabolic syndrome was highly predictive of 
new-onset diabetes16. Almost half of the population-attributable risk for diabetes could 
be explained by the presence of ATP III metabolic syndrome.
Diabetes as a Predictor of CVD
Framingham data showed that most men with diabetes had a 10-year risk for CHD 
>  20%;  in  contrast,  women  rarely  exceeded  the  20%  level.  Oxford  investigators 
therefore have developed a risk engine (available on the World Wide Web) based on the 
large UK Prospective Diabetes Study (UKPDS) database,  which had 500 hard CHD 
events5,16.  It  differs from the Framingham algorithm in that  it  includes a measure of 
glycemia and duration of diabetes.  Surveys of other diabetic populations by UKPDS 
investigators  found  that  Framingham  equations  considerably  underestimate  risk  for 
CHD and stroke, whereas the UKPDS Risk Engine provides a more robust estimate.
Metabolic Syndrome Associated With Increased CV Morbidity and Mortality16,18
Waist Circumference and cardiovascular events16,18
ATP III Guidelines for the Treatment of Patients with Metabolic Syndrome11,17  
                      
Pharmacotherapeutic strategies targeting the Metabolic syndrome
ACE-inhibitors (ACE-I) and AT1-receptor antagonists (ARBs)
Insulin resistance is known to activate the RAS [DeFronzo and Ferrannini, 1991]. 
Angiotensin  II  as  the  main  effector  of  the  RAS  not  only  increases  the  vascular 
resistance,  but  also  increases  hepatic  glucose  production  and  decreases  insulin 
sensitivity. Therefore it is obvious that pharmacological inhibition of the RAS does not 
only exert antihypertensive effects but also targets insulin resistance and improves the 
glucose metabolism. The question whether an ACE-I or an angiotensin receptor blocker 
(ARB) should be used remains controversial. There is consensus that ARBs may be used 
when ACE-I are not tolerated and have similar beneficial effects in preventing diabetes 
[Barnett  et al.  2004]. In contrast to ACE-I, ARBs directly block the AT1-receptor and 
hence also the action of angiotensin II produced via non-ACE-dependent pathways20. 
However, there are two additional pharmacological arguments supporting the use of an 
ARB.  ARB  results  in  significant  increases  of  the  pleiotropic  and  vasodilatory 
angiotensin II – metabolite angiotensin 1-7 [Ang-(1-7)] [Schindler  et al.  2007], which 
might improve the antihypertensive effects, whereas treatment with an ACE-I results in 
increases of bradykinin-levels, which do not seem to have beneficial vascular effects 
[Schindler  et  al.  2007].  These  observations  suggest  telmisartan  as  a  promising 
cardiometabolic ARB, which targets the RAS via selective AT1-receptor antagonism 
and insulin resistance via binding to the intracellular PPAR γ -complex, which has been 
shown to improve insulin resistance. 
Endothelin (ET)-Antagonists
Cardillo et al. have shown that selective ET-A-blockade in the forearm resulted in 
a significant increase in forearm blood flow (FBF) in patients with type II diabetes but 
not in healthy individuals, whereas nonselective ET-A/ET-B blockade in diabetics did 
not  significantly  modify  the  effects  of  ET-A  antagonism  [Cardillo  et  al.  2002a]20. 
Considering a potential role for endothelin in hypertension and in insulin resistant states 
especially  with  respect  to  the  ability  of  angiotensin  II  to  stimulate  ET  production, 
endothelin-antagonists might be an additional therapeutic option for treating the MetS, 
maybe in combination with a drug inhibiting the RAS. 
Calcium channel blockers (CCBs)
CCBs appear to have beneficial effects with respect to maintenance of renal blood 
flow and glomerular filtration rate [Sowers, 1997b].
PPAR-receptor complex stimulation as therapeutical target
PPARs  are  ligand-activated  transcription  factors  and  belong  to  the  nuclear 
receptor super family, which also includes the steroid and thyroid hormone receptors. 
The PPAR family consists  of  three members,  α,  γ  and  β/δ,  which share 60 to 80% 
homology  in  their  ligand-  and  DNA-binding  domains.  PPARα  can  be  activated  by 
certain  polyunsaturated  fatty  acids,  by  oxidized  phospholipids  and  by  lipoprotein 
lipolytic  products  [Ziouzenkova  et  al.  2003].  Fibrates  and  gemfibrocil  are  synthetic 
ligands  [Formann  et  al.  1997],  which  are  used  as  drugs  for  the  treatment  of 
hypertriglyceridemia [Yuan  et al.  2007]. PPARα  regulates genes that are involved in 
lipid and lipoprotein metabolism. PPARγ is activated by prostaglandin-derivatives and 
forms of oxidized linoleic acid as natural ligands. Synthetic ligands currently available 
for  drug  treatment  include  the  thiazolidinediones  (glitazones)19 rosiglitazone  and 
pioglitazone.  Glitazones  functioning as PPARγ  –activators play an important role in 
glucose homeostasis  and reduce peripheral  insulin  resistance of  patients  with type 2 
diabetes [Saltiel and Olefsky, 1996]19,20. PPARα/γ dual agonists such as muraglitazar or 
tesaglitazar have been developed to target both PPARα  and PPARγ  simultaneously in 
order to produce synergistic antidiabetic and cardioprotective effects24.  Dual agonists 
have been demonstrated to reduce triglycerides, raise cardioprotective HDL levels and 
consequently improve insulin sensitivity [Kendall et al. 2006].
Statins
The pleiotropic effects of statins improves cardiovascular outcomes beyond their 
ability  to  improve  atherogenic  lipid profiles  [McFarlane  et  al.  2002].  Modulation of 
endothelial  function,  plaque stabilization,  attenuated atherogenesis,  anti-inflammatory 
and antithrombotic effects might support the cardiometabolic risk reduction in patients 
with the Metabolic Syndrome.
CETP-inhibition with torcetrapib
CETP-inhibition has been regarded as a promising therapeutic concept to reduce 
the total cardiovascular risk. However, the CETP-inhibitor drug torcetrapib, which was 
designed to selectively increase HDL-levels by blocking CETP showed that, although 
the drug raises HDL as expected, it doesn’t halt the progression of atherosclerosis21.
Sibutramine, orlistat and rimonabant
Sibutramine, a centrally acting appetite suppressant, and orlistat, a locally acting 
inhibitor of nutrient absorption, pharmacologically target obesity as a component of the 
MetS. Sibutramine acts on the CNS by inhibiting the reuptake of norepinephrine and 
serotonin  and  thereby  amplifies  satiety  signals  that  induce  a  sensation  of  fullness24. 
Orlistat  is a drug that reduces fat absorption by binding to pancreatic lipases, which 
partially  inhibits  the  hydrolysis  of  triglycerides  into  absorbable  free  fatty  acids  and 
monoacylglycerols [Yanovski et al. 2002].
Rimonabant is a selective cannabinoid-1 receptor blocker. The endocannabinoid 
system plays a role in the central and peripheral regulation of body weight and energy 
balance [Van Gaal  et al. 2005]. Three Rimonabant In Obesity/Overweight (RIO)-trials 
demonstrated  that  the  drug  reduces  weight  and  waist  circumference  and  improves 
numerous  cardiovascular  and  metabolic  risk  factors.  In  all  trials,  rimonabant  was 
associated with an increased HDL cholesterol and decreased waist circumference and 
triglycerides25.
Current  Therapies  Often  Address  Individual  Risk  Factors  Instead  of  a  Root 
Cause22,23
  
AIM AND OBJECTIVES OF THE STUDY
• To  evaluate  the  effects  of  the  metabolic  syndrome  on  echocardiographically 
determined left ventricular structure and function.
• To evaluate the systolic and diastolic dysfunction in patients with the metabolic 
syndrome.
                                         
MATERIALS AND METHODS
Clinical setting 
      The people attending diabetic outpatients clinic with impaired fasting glucose and 
impaired glucose tolerance for regular follow up. 
Collaborating departments 
 Department of Diabetology, 
Madurai Medical College, 
Madurai. 
Department of Biochemistry, 
Madurai Medical College, 
Madurai. 
Design of study : case control study 
Period of study: 1 year 
Sample size: 100 cases and 25 controls 
Study population 
 Cases 
      Among  the  people  attending  diabetic  outpatients  clinic  with  impaired  fasting 
glucose and impaired glucose tolerance for regular follow up, 100 people with waist 
circumference satisfying the criteria for the metabolic syndrome were selected.
              Males    – 50
              Females – 50 
 Controls
      Healthy  attenders  accompanying  the  follow  up  patients  and  diabetic  patients, 
screened for plasma glucose and having normal waist circumference. The number of 
controls included in the study was 25. 
Inclusion criteria 
- Males  and females  who satisfy  the  criteria  for  the definition  of  the  metabolic 
syndrome.
- They did not have established coronary artery disease, as evidenced by a negative 
Treadmill test.
- They had normal LV systolic function.
Exclusion criteria 
- History  or  findings  suggesting  cardiovascular  disease  including  heart  failure 
symptoms, or systolic dysfunction, coronary artery disease, significant valvular 
heart disease, and/ or hypertrophic cardiomyopathy.
- Pregnancy and lactating mothers.
- Those who had major systemic illness.
The metabolic syndrome was defined according to IDF criteria and is as follows : 
          Central obesity (defined as waist circumference  ≥90 cm for  men and  ≥80 cm 
for  women.
Plus any 2 of the following 4 factors:
- Raised  triglyceride  level  ≥150  mg/dL,  or  specific  treatment  for  this  lipid 
abnormality
- Reduced  HDL-C  <40  mg/dL  in  males,  <50  mg/dL  in  females,  or  specific 
treatment for this lipid abnormality
- Raised  BP:  systolic  BP  ≥130  or  diastolic  BP  ≥85  mm  Hg,  or  treatment  of 
previously diagnosed hypertension.
- Raised  fasting  plasma  glucose  ≥100  mg/dL,  or  previously  diagnosed  type  2 
diabetes.
Study method
All  the  study  subjects  and  controls  underwent  a  complete  cardiovascular 
evaluation after an 8 hours fast including 
- History and physical examination
- Heart  rate  and blood pressure  (obtained after  10 minutes of  rest  in the sitting 
position, expressed as the average of 3 consecutive measurements  in each arm)
- Fasting and postprandial plasma glucose.
- Fasting lipid profile
- A  comprehensive  2D  and  Doppler  echocardiogram,  along  with  3D  strain 
echocardiographic evaluation.
We had obtained permission from ethical committee for the study.
Informed consent was obtained from each patient, prior to study enrollment.
After this initial evaluation clinically and biochemically, cases were selected using 
the International Diabetes Federation criteria for the diagnosis of metabolic syndrome. 
25 controls were enrolled, who had normal waist circumference and do not meet other 
criteria. In the cases group, 10% were in the age group of <40 years, 76% were between 
40 and 60 years, and 14% were >60 years.
         The frequency of various components of metabolic syndrome changed from 3 
components in 14%, 4 components in 68%, to 5 components in 18%.
       Then the prevalence of the various components of the metabolic syndrome were 
analysed.  100% of  the  cases  met  the  criteria  for  waist  circumference  and  impaired 
fasting  glucose/  impaired  glucose  tolerance.  80%  of  the  cases  had  elevated  blood 
pressure, 74% had increased triglycerides level and 52% had decreased HDL levels.
Echocardiographic evaluation
         The  patients  and  controls  underwent  two  dimensional,  M-mode,  and  Doppler 
echocardiography according to a standardized protocol.
         Echocardiography was performed using dedicated 3D echocardiographic system, 
Philips iE 33 with QLAB software and Aloka SSD 4000 Echocardiography Sysetm.
         First left ventricular internal dimensions and wall thickness were measured using 
standard recommendations and ejection fraction was found using M-mode and Simpson 
method.
EF calculation from volume data obtained by Simpson method:
Stroke volume = End diastolic volume (EDV) – End systolic volume (ESV)
          EDV – ESV 
EF = x 100%
              EDV 
Left atrial diameter was measured in parasternal long axis view.
Relative wall thickness was measured as follows:
         Posterior wall thickness + IVS thickness 
RWT =
LV interior dimension
LV mass was calculated using the formula
LV mass = (IVS+LVID+PW)3 – LVID3 X 1.05 g/cm3
LV mass was indexed to body surface area to get LV mass index.
Left  ventricular  hypertrophy was  diagnosed when the  LV mass   index was  ≥ 
131g/m2 in men and ≥ 100g/m2 in women. Increased relative wall thickness+ normal LV 
mass is concentric remodeling. Increased relative wall thickness + increased LV mass is 
concentric hypertrophy. Normal relative wall thickness + increased LV mass is eccentric 
hypertrophy.
          In all the patients and controls, diastolic dysfunction was assessed by pulsed-wave 
Doppler  examination  of  mitral  flow  (before  and  during  Valsalva  maneuver)  and 
pulmonary venous inflow, as well as by Doppler tissue imaging of the mitral annulus. 
Diastolic  dysfunction  was  graded  on a  4-point  ordinal  scale:  normal;  mild  diastolic 
dysfunction, defined as abnormal relaxation without increased LV end-diastolic filling 
pressure  (peak early  (E)  to  peak late  [atrial]  [A]  diastolic  filling velocity  ratio  <1); 
moderate or “pseudonormal” diastolic dysfunction, defined as abnormal relaxation with 
increased LV end-diastolic filling pressure (E/A ratio of  1 to 2, deceleration time >140 
ms, and 2 other Doppler indices of elevated LV end-diastolic filling pressure); or severe 
diastolic  dysfunction,  defined  as  advanced  reduction  in  compliance  with  restrictive 
filling (E/ A ratio >2, deceleration time <140 ms, and Doppler indices of elevated LV 
end-diastolic filling pressure). For patients in atrial fibrillation, diastolic function was 
classified  as  indeterminate  unless  restrictive  physiologic  factors  (E/A  ratio  >1.5, 
deceleration time <140 ms) were present.
The pulse wave doppler study of right upper pulmonary venous flow was done. There 
were systolic (S), diastolic (D), and atrial reversal (Ar) waves. In normal and grade 1 
diastolic dysfunction, S ≥ D and Ar duration < A duration. In Grade II, grade III and 
Grade IV diastolic dysfunction, S<D and  Ar duration > A duration+ 30ms.  
          Then Tissue Doppler imaging  study with sample volume on the septal side of the 
mitral annulus was done and the S’, E’, and A’ waves were obtained. In normal and 
Grade  I  diastolic  dysfunction,  E/E’  was  <10.  In  Grade  II,  Grade  III,  and Grade IV 
diastolic dysfunction, E/E’ was ≥ 10. 
      From  the  tissue  Doppler  image, the  values  of  isovolumic  contraction  time, 
ejection  time  and  isovolumic  relaxation  time  were  obtained.  The  myocardial 
performance index or Tei index was obtained using the formula,
                     MPI =  IVCT + IVRT  / ET.
MPI  values  were  elevated  in  patients  who  had  either  systolic  or  diastolic 
dysfunction. 
         
Normal PW-TDI spectral curve: note the immediate representation of the 
mechanical events in the various phases of the cardiac cycle.
Then  all  the  patients  underwent  strain  imaging  with  speckle  tracking 
echocardiography  and  parametric  images  were  obtained.  From  these  images,  peak 
systolic strain and early diastolic strain and strain rate were obtained.
End diastole                               End systole
     
The longitudinal strain, radial strain, and radial strain rate were obtained for 50 
cases  and  10 controls  were  obtained.  The  strain  values  and  strain  rate  values  were 
analysed.
STATISTICAL ANALYSIS 
The  information  collected  regarding all  the  selected  cases  were  recorded in  a 
master chart. Data analysis was done with the help of computer using Epidemiological 
information package (EPI 2002). Using this software, frequencies, percentages, mean, 
standard deviation, α 2 and ‘p’ values are calculated. A ‘p’ value less than 0.05 is taken 
to denote significant relationship.
OBSERVATIONS
The  observations  in  the  study  related  to  the  characteristics  of  the  cases  and 
controls, their biochemical profile and echocardiographic abnormalities were analysed.
         In the study population of 100 cases, 50 were males and 50 were females.
The age distribution of the cases and controls is shown in table 1
                                                Table 1
              Distribution of cases and controls according to age
Age group Cases (%) Controls (%)
         < 40 years      10  ( 10% )     3   ( 12% )
        40 – 60 years      76  ( 76% )    19  ( 76% )
> 60 years      14  ( 14% )     3   ( 12% )
   
     
In Table 2, the frequency of various components of metabolic syndrome in the 
study cases are shown.
Table 2
Frequency of the components of metabolic syndrome
Number of components Number of patients (%)
             Three           14   ( 14% )
              Four           68   ( 68% )
              Five           18   ( 18% )
 
In  table  3,  the  prevalence  of  various  components  of  metabolic  syndrome  are 
listed.  Since  we  followed  IDF  criteria  for  metabolic  syndrome,  100%  of  patients 
satisfied the waist circumference criteria. 100% of patients had IFG / IGT.
Table 3
Prevalence of components of metabolic syndrome
No. Components Percentage of 
prevalence
     1. Waist circumference
- In males > 90 cm
- In females > 80 cm
        100%
        100%
     2. Blood pressure  ≥ 130/85 mm Hg          80%
     3. Impaired  fasting  glucose  / 
Impaired glucose tolerance
        100%
     4. Triglycerides  ≥ 150 mg %         74%
     5. High density lipoprotein
- In males   < 40 mg%
- In females < 50 mg%
        52%
        20%
        32%
        
Table 4
Characteristics of the study cases and controls
No. Characteristics Cases Controls
  1.     Mean age (years) 51 ± 11 48 ± 10
  2.     BMI  ( Kg/ m2 ) 28 ± 3 23 ± 2
  3.   Waist circumference (cm) 94 ± 6 82 ± 5
  4. Systolic blood pressure (mm Hg) 148 ± 7 136 ± 6
  5. Diastolic blood pressure (mm Hg) 92 ± 4 81 ± 4
  6. Fasting plasma glucose (mg%) 114 ± 5 92 ± 8
  7. Postprandial plasma glucose (mg
%)
156 ± 10 104 ± 10
  8. Total cholesterol (mg%) 200 ± 18 190 ± 12
  9. LDL cholesterol (mg%) 126 ± 30 120 ± 14
  10. HDL cholesterol (mg%) 43 ± 9 46 ± 10
  11. Triglycerides 172 ± 20 148 ± 10
  12. VLDL cholesterol (mg%) 40 ± 6 36 ± 5
Table 5
Echocardiographic abnormalities
 No.             Parameters In  cases In controls P value
 1. LVID  ( diastole )  (mm)
LVID  ( systole )    (mm)
47 ± 5
32 ± 5
45 ± 4
30 ± 4
  2. Ejection fraction 59 ± 4 60 ± 5
  3. LV mass ( gm ) 180 ± 40 158 ± 22
  4. LV mass index ( gm/m2 ) 105 ± 22 92 ± 16 <0.0001
  5. Relative wall thickness 0.45 ± 0.3 0.39 ± 0.3 <0.0001
  6. Left atrial diameter ( cm ) 3.8 ± 0.4 3.4 ± 0.4 0.002
  7. PWD – mitral inflow 
- E wave ( cm/s )
- A wave ( cm/s )
- E/A ratio 
- Deceleration time (ms)
- IVRT (ms)
74 ± 16
64 ± 14
1.2 ± 0.5
188 ± 20
88 ± 10
70 ± 10
48 ± 12
1.5 ± 0.4
160 ± 16
70 ± 8
<0.0001
<0.0001
<0.0001
0.002
  8. PWD – pulmonary venous flow
- S wave (cm/s)
- D wave (cm/s)
- Ar wave (cm/s)
52 ± 8
47 ± 8
31 ± 5
54 ± 8
44 ± 6
30 ±7
  9. Tissue Doppler imaging
- S’  (cm/s)
- E’  (cm/s)
- A’  (cm/s)
8 ± 2
8 ± 2
9 ± 3
8 ± 2
10 ± 2
8 ± 3
<0.0001
  10.    E/E’ 10 ± 2 8 ± 1
   1.   IVCT (ms) 37 ± 5 35 ± 5
  12.   IVRT  (ms) 86 ± 10 70 ± 10 0.002
  13.   Ejection time  (ms) 262 ± 10 290 ± 30
  14. Myocardial performance index 0.45 ± 0.08 0.35 ± 0.04 <0.0001
In  table  6,  the  number  of  patients  having  concentric  remodeling,  concentric 
hypertrophy, and eccentric hypertrophy are shown.
Table 6
Distribution of changes in left ventricular structure
No. Change in LV structure Percentage of
cases (%)
    1. Concentric remodelling 50%
    2. Concentric hypertrophy 12%
    3. Eccentric hypertrophy ---
In table 7, the percentage of patients in each class of diastolic dysfunction are 
shown.
                                            
Table 7
Percentage of cases and controls having diastolic dysfunction
Grading of diastolic dysfunction In cases In controls
  No diastolic dysfunction 46 %
Grade I diastolic dysfunction 40 % 21 %
Grade II diastolic dysfunction 14 % ---
Grade III & IV diastolic dysfunction ---- ---
In table 8, we have correlated patients having diastolic dysfunction in metabolic 
syndrome with myocardial performance index and there is a direct correlation between 
increasing grades of diastolic dysfunction and elevated MPI.
Table 8
             Correlation between grading of diastolic dysfunction and MPI
No. Patients with diastolic 
dysfunction
MPI P-value
  1.  No diastolic dysfunction  0.36 ± 0.03
  2.  Grade I diastolic dysfunction  0.44 ± 0.04   <0.0001
  3.  Grade II diastolic dysfunction  0.50 ± 0.04   <0.0001
Strain imaging by speckle tracking echocardiography
          Table 9 shows the mean strain imaging values of various segments in patients 
with metabolic syndrome, compared with controls.
Table 9
Peak systolic strain
No. Longitudinal strain in 
segments
In cases ( %) In controls (%)
  1. Basal septal 9 ± 2 15 ± 2
  2. Mid septal 7 ± 1 18 ± 3
  3. Apical septal 14 ± 3 14 ± 2
  4. Apex 12 ± 3 14 ± 2
  5. Apicolateral 15 ± 3 15 ± 4
  6. Mid lateral 21 ± 3 22 ± 4
  7. Basal lateral 25 ± 3 26 ± 4
Radial strain in segments
  1. Basal septal 20 ± 5 26 ± 5
  2. Mid septal 22 ± 4 28 ± 3
  3. Apical septal 28 ± 4 29 ± 6
  4. Apex 22 ± 4 27 ± 4
  5. Apicolateral 26 ± 3 27 ± 5
  6. Midlateral 30 ± 5 32 ± 6
    7. Basal lateral 29 ± 4 33 ± 5
Radial strain rate in segments Cases ( s-1 )
    1. Basal septal 1.4 ± 0.2 2.0 ± 0.3
    2. Midseptal 1.5 ± 0.3 2.2 ± 0.4
    3. Apical septal 1.5 ± 0.2 1.9 ± 0.3
    4. Apex 1.5 ± 0.3 1.5 ± 0.3
    5. Apicolateral 1.7 ± 0.4 2.1 ± 0.2
    6. Midlateral 1.8  ± 0.4 1.9 ± 0.2
    7. Basal lateral 1.9 ± 0.2 2.0 ± 0.3
Early diastolic strain
Longitudinal strain Cases (%) Controls (%)
   1. Basal septal 9 ± 2 14 ± 2
   2. Mid septal 8 ± 3 15 ± 2
   3. Apical septal 16 ± 3 16 ± 2
  4.  Apex 15 ± 2 15 ± 3
  5. Apical lateral 16 ± 3 18 ± 2
  6. Mid lateral 22 ± 5 27 ± 5
    7. Basal lateral 28 ± 4 28 ± 3
Radial strain in segments
    1. Basal septal 20 ± 4 28 ± 4
  2. Mid septal 26 ± 4 28 ± 5
  3. Apical septal 25 ± 8 27 ± 5
  4. Apex 26 ± 4 25 ± 6
  5. Apical lateral 28 ± 3 27 ± 5
  6. Mid lateral 32 ± 5 32 ± 6
  7. Basal lateral 38 ± 5 39 ± 5
 Radial strain rate in segments
  1. Basal septal 1.5  ± 0.3 1.8 ± 0.2
  2. Mid septal 1.6 ± 0.4 2.0 ± 0.3
  3. Apical septal 1.6 ± 0.2 1.9 ± 0.2
 4. Apex 1.4 ± 0.2 1.5 ± 0.2
  5. Apical lateral 1.6 ± 0.2 2.0 ± 0.3
  6. Mid lateral 1.5 ± 0.3 2.1 ± 0.4
  7. Basal lateral 2.2 ± 0.3 2.5 ± 0.3
LIMITATIONS OF THE STUDY  
In spite of meticulous conduct of the study, we have limitations in our study. Our 
Philips iE 33 echocardiography system is using Q LAB software. In this, we were not 
able to track the cardiac borders accurately in short axis. So, our values related to Radial 
strain differ while comparing with certain references. 
CONCLUSION
The following conclusion was derived from this study.
1. The  prevalence  of  Diastolic  dysfunction  is  relatively  high  in  patients  with 
metabolic syndrome when compared to controls.
2. There is a significant change in LV structural characteristics in   patients with 
metabolic syndrome when compared to controls. The parameters like LV mass, 
LV  mass  index,  and  relative  wall  thickness  were  significantly  increased  in 
patients  with  metabolic  syndrome.  Concentric  remodeling  was  more  common 
than concentric hypertrophy and eccentric hypertrophy in patients with metabolic 
syndrome
3. With  the  Pulse  Doppler  echocardiographic  evaluation   of  mitral  inflow, 
pulmonary  venous  flow,  and  tissue  doppler  imaging  at  mitral  annulus,  and 
applying  the  criteria  for  diastolic  dysfunction,  the  prevalence  of   diastolic 
dysfunction is nearly 54% in patients with metabolic syndrome ( Grade I diastolic 
dysfunction- 40% and Grade II diastolic dysfunction – 14%) when it is 21% in the 
controls.
4. Impaired  relaxation  (Grade  I  diastolic  dysfunction)  is  more  prevalent  among 
patients  with  metabolic  syndrome  and  signified  subclinical  LV  diastolic 
dysfunction with masked cardiovascular disease.
5. Left  Ventricular  Myocardial  Performance  Index  measured  by  Tissue  Doppler 
Imaging, is having good correlation with the prevalence and degree of diastolic 
dysfunction.
6. Finally, strain imaging in patients with metabolic syndrome with normal ejection 
fraction  shows  subclinical  LV  systolic  dysfunction  in  addition  to  diastolic 
dysfunction, as evidenced by a decreased peak systolic strain.
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                                                           PROFORMA
ECHOCARDIOGRAPHIC ABNORMALITIES IN THE METABOLIC 
SYNDROME
Name of the patient   :                                       Age :                    Sex:
CD no :                                                              Address :
Clinical diagnosis      :
Brief history              :
General examination :
Build and nourishment
Height
Weight
Waist circumference
Hip measurement
Waist hip ratio
Pulse   :
Blood pressure :
Cardiovascular system examination :
Respiratory system examination :
Abdomen  :
CNS examination:
Investigations :
Urine   -    Albumin
- Sugar
-  Deposits
Blood  - Hb 
-         ESR
Blood urea
Blood sugar - F
                     - PP
Serum creatinine
Fasting lipid profile
         Total – C           LDL – C           HDL – C
          TGL           VLDL
ECG
Echocardiogram :
2 D and M mode echo :    
                     LVID (d)                     LVID (s)
                     EF                      LV mass
                     LV mass index Relative wall thickness
                     Left atrial diameter          RWMA
Doppler echo :
         Mitral inflow  : E
                                  A
                                 DT
                                   E/A
        Pulmonary venous flow –  S
                                                   D
                                                   A
         TDI                     -  S’                  E’
                                        A’ IVCT
                                        IVRT            ET
                                       MPI
3 D echo:
Strain echo findings:
